| 1611. Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Experienced People With HIV and a History of … B Trottier, F Bonnet, M Garcia-Deltoro, M Andreoni, M Boffito, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 1446, 2023 | | 2023 |
| A diabetic patient with blisters CM Donkers, BJ van Welzen, HW de Valk Nederlands Tijdschrift Voor Geneeskunde 161, D838-D838, 2017 | | 2017 |
| A highly virulent variant of HIV-1 circulating in the Netherlands C Wymant, D Bezemer, F Blanquart, L Ferretti, A Gall, M Hall, T Golubchik, ... Science 375 (6580), 540-545, 2022 | 60 | 2022 |
| A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing? BJ van Welzen, T Mudrikova, A El Idrissi, AIM Hoepelman, JE Arends Infectious diseases and therapy, 1-18, 2019 | 80 | 2019 |
| Acute severe hepatitis outbreak in children: A perfect storm. What do we know, and what questions remain? PC Matthews, C Campbell, O Săndulescu, M Matičič, SM Ruta, ... Frontiers in pharmacology 13, 1062408, 2022 | 22 | 2022 |
| Assessing and improving the quality of guideline-adherent hepatitis B virus care in people with HIV: A cross-sectional study PGA Oomen, VJP van Kraaij, AM Gerritsma, FM Verduyn Lunel, ... International journal of STD & AIDS, 09564624231203735, 2023 | | 2023 |
| Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for the Treatment of People Living with HIV (PLWH): 12-month (12M) Effectiveness, Persistence, and Safety in a Multi … J Mallolas, V Esposito, L Hocqueloux, JS Lambert, I Levy, C Wyen, ... Mediterranean Journal of Infection, Microbes & Antimicrobials 11, 2022 | 3 | 2022 |
| Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV: 24-month (24M) analyses by age, race, sex, adherence and late … B Trottier, A Antinori, J De Wet, C Duvivier, H Elinav, S Esser, J Ghosn, ... JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 25, 69-70, 2022 | 4 | 2022 |
| Brief report: Low sensitivity of the fracture risk assessment tool in young HIV-infected patients: Time to revise our screening strategy BJ van Welzen, S Yesilay, JE Arends, AIM Hoepelman, T Mudrikova JAIDS Journal of Acquired Immune Deficiency Syndromes 82 (5), 439-442, 2019 | 1 | 2019 |
| Cabotegravir plus Rilpivirine longacting efficacy and safety outcomes by sex at birth, age and race: A subgroup analysis of the CARISEL study J Ghosn, L Hocqueloux, MJ Crusells-Canales, L Belkhir, ... HIV MEDICINE 24, 187-188, 2023 | | 2023 |
| Changes in inflammatory and atherogenesis biomarkers with the 2-drug regimen dolutegravir plus lamivudine in antiretroviral therapy–experienced, virologically suppressed people … JM Llibre, PE Cahn, J Lo, TJ Barber, C Mussini, BJ van Welzen, ... Open Forum Infectious Diseases 9 (4), ofac068, 2022 | 23 | 2022 |
| Clinical Outcomes of Integrase Strand Transfer Inhibitors Containing Antiretroviral Therapy in HIV-2: A Narrative Review WJ Boschloo, BJ van Welzen Infectious Diseases and Therapy, 1-15, 2024 | | 2024 |
| Decreased all-cause and liver-related mortality risk in HIV/hepatitis B virus coinfection coinciding with the introduction of tenofovir-containing combination antiretroviral … BJ van Welzen, C Smit, A Boyd, FI Lieveld, T Mudrikova, P Reiss, ... Open forum infectious diseases 7 (7), ofaa226, 2020 | 21 | 2020 |
| Dolutegravir/lamivudine is clinically non-inferior to dolutegravir-based triple drug antiretroviral therapy: 1-year results of the DUALING real-world nationwide prospective … M Vasylyev, F Wit, C Jordans, R Soetekouw, S van Lelyveld, G Kootstra, ... JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 25, 78-79, 2022 | | 2022 |
| Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir-and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human … M Vasylyev, FWNM Wit, CCE Jordans, R Soetekouw, SFL van Lelyveld, ... Open forum infectious diseases 11 (4), ofae160, 2024 | | 2024 |
| Dual antiretroviral therapy—all quiet beneath the surface? BJ Van Welzen, PGA Oomen, AIM Hoepelman Frontiers in Immunology 12, 637910, 2021 | 13 | 2021 |
| Dynamics of Low-Level Viremia and Immune Activation after Switching to a Darunavir-Based Regimen AJ Stam, NVEJ Buchholtz, WFW Bierman, R van Crevel, AIM Hoepelman, ... Viruses 16 (2), 182, 2024 | 1 | 2024 |
| Een diabeet met blaren CMJ Donkers, BJ Van Welzen, HW De Valk Nederlands Tijdschrift voor Geneeskunde 161 (10), 2017 | | 2017 |
| Efficacité et sécurité à 24 mois (24M) de bictegravir/emtricitabine/ténofovir alafenamide (B/F/TAF) chez les personnes vivant avec le VIH (PVVIH) naïves (TN) et déjà traitées … MG Deltoro, M Waizmann, O Robineau, E Shahar, JS Lambert, ... Médecine et Maladies Infectieuses Formation 2 (2), S78, 2023 | | 2023 |
| Efficacy, safety and implementation outcomes of Cabotegravir plus Rilpivirine long-acting by country in the Cabotegravir and rilpivirine implementation study in European … C Jonsson-Oldenbuettel, J Ghosn, JO Sierra, M van der Valk, T Lutz, ... HIV MEDICINE 24, 193-195, 2023 | | 2023 |
